{"id":8194,"date":"2020-02-11T17:00:04","date_gmt":"2020-02-11T11:30:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8194"},"modified":"2021-07-24T12:57:47","modified_gmt":"2021-07-24T07:27:47","slug":"recent-pharma-happenings-for-kite-aquestive-milliporesigma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma","title":{"rendered":"Good news for Kite\u2019s KTE-X19, and Aquestive\u2019s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma"},"content":{"rendered":"\n

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL)<\/strong><\/h2>\n\n\n\n

The drug– KTE-X19<\/strong>, which is an investigational chimeric antigen receptor (CAR) T cell therapy treatment method for curing relapsed or refractory mantle cell lymphoma<\/a> (MCL), has received a Priority Review designation. <\/p>\n\n\n\n

The recommendation came after the data from the single arm, open-label, Phase 2 ZUMA-2 trial, which revealed 93 percent of patients responded to a single infusion of KTE-X19, including 67 percent of patients achieving a complete response, as assessed by an Independent Radiologic Review Committee. <\/p>\n\n\n\n

A subsidiary of Gilead Sciences, Kite pharma, focusing on the development of Cancer <\/a>therapies, already has one therapy marketed- Yescarta (axicabtagene ciloleucel), for curing diffuse large B-cell lymphoma<\/a>; and if the FDA rules in favour of the recent one, Gilead would be able to occupy the major Gene therapy market share. <\/p>\n\n\n\n

The US FDA has accepted Aquestive Therapeutics\u2019 NDA for Libervant (diazepam) Buccal Film for seizure clusters. <\/strong><\/h2>\n\n\n\n

Libervant<\/strong> is a soluble film of formulation of diazepam, is administered on the inner side of the cheek. It is designed as a fast treatment to provide relief from acute uncontrolled seizures <\/a>in refractory patients with epilepsy <\/a>on stable anti-epileptic drugs (AEDs). <\/p>\n\n\n\n

With Orphan drug designation granted in 2016, and target action date of September 27, 2020, if the therapy gets FDA approval, it would be the first oral diazepam-based therapy approved for seizure clusters. <\/p>\n\n\n\n

The submission of the NDA was backed by the results from the study that supported the administration of Libervant for the treatment of Epileptic patents.
<\/p>\n\n\n\n

ReForm Biologics LLC and MilliporeSigma have announced a global license agreement and collaboration for the development and commercialization of excipients. <\/strong><\/h2>\n\n\n\n

Under the agreement, MilliporeSigma and ReForm Biologics- a US-based pharma tech company- will carry out research, and develop ReForm Biologics\u2019 excipients for pharmaceutical use.<\/p>\n\n\n\n

On the other hand, MilliporeSigma will fund the research and development and will manage the global commercialization, GMP manufacturing, and sale of ReForm Biologics\u2019 excipients to MilliporeSigma\u2019s customers for use in biologic formulations.<\/p>\n\n\n\n

ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics\u2019 technology to MilliporeSigma\u2019s customers in biologic formulations.
<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL) The drug– KTE-X19, which is an investigational chimeric antigen receptor (CAR) T cell therapy treatment method for curing relapsed or refractory mantle cell lymphoma (MCL), has received a Priority Review designation.  The […]<\/p>\n","protected":false},"author":1,"featured_media":8196,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16919,18024,16830,18025,349,18027,18029,639,5789,18028,18026],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-8194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aquestive-therapeutics","tag-biological-license-application","tag-diffuse-large-b-cell-lymphoma","tag-kte-x19","tag-latest-pharma-news","tag-libervant","tag-milliporesigma","tag-pharma-news","tag-recent-pharma-news","tag-reform-biologics-llc","tag-relapsed-or-refractory-mantle-cell-lymphoma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nKite's CAR-T cell therapy; NDA for Libervant; ReForm Biologics pact<\/title>\n<meta name=\"description\" content=\"The drug- KTE-X19, an investigational CAR T cells therapy treatment method for curing relapsed mantle cell lymphoma has received a Priority Review...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kite's CAR-T cell therapy; NDA for Libervant; ReForm Biologics pact\" \/>\n<meta property=\"og:description\" content=\"The drug- KTE-X19, an investigational CAR T cells therapy treatment method for curing relapsed mantle cell lymphoma has received a Priority Review...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-11T11:30:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kite's CAR-T cell therapy; NDA for Libervant; ReForm Biologics pact","description":"The drug- KTE-X19, an investigational CAR T cells therapy treatment method for curing relapsed mantle cell lymphoma has received a Priority Review...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma","og_locale":"en_US","og_type":"article","og_title":"Kite's CAR-T cell therapy; NDA for Libervant; ReForm Biologics pact","og_description":"The drug- KTE-X19, an investigational CAR T cells therapy treatment method for curing relapsed mantle cell lymphoma has received a Priority Review...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-11T11:30:04+00:00","article_modified_time":"2021-07-24T07:27:47+00:00","og_image":[{"width":768,"height":480,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma","name":"Kite's CAR-T cell therapy; NDA for Libervant; ReForm Biologics pact","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news.jpg","datePublished":"2020-02-11T11:30:04+00:00","dateModified":"2021-07-24T07:27:47+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The drug- KTE-X19, an investigational CAR T cells therapy treatment method for curing relapsed mantle cell lymphoma has received a Priority Review...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kite-aquestive-milliporesigma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news.jpg","width":768,"height":480,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/11165532\/11-feb-2020_news-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aquestive Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biological License Application<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diffuse Large B Cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">KTE X19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Libervant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MilliporeSigma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ReForm Biologics LLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aquestive Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Biological License Application<\/span>","<span class=\"advgb-post-tax-term\">Diffuse Large B Cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">KTE X19<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Libervant<\/span>","<span class=\"advgb-post-tax-term\">MilliporeSigma<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">ReForm Biologics LLC<\/span>","<span class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 11, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 11, 2020 5:00 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8194"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8194\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8196"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8194"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8194"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}